贝伐珠单抗联合表皮生长因子受体络氨酸激酶抑制剂治疗非小细胞肺癌的研究进展

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Lung cancer is the most common malignancy with the highest morbidity and mortality worldwide, most of which are non-small cell lung cancer (NSCLC).Epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKI) drugs significantly prolonged the survival time of NSCLC patients, but most patients developed drug resistance.Bevacizumab inhibited the activity of human vascular endothelial growth factor and inhibited the formation of blood vessels effectivly, which has better antitumor effect.Bevacizumab and EGFR-TKI drugs act on different tumor growth pathways, and these two drugs have potentially complementary mechanisms to control tumor.The combined treatment of NSCLC has sufficient theoretical basis and application prospect.This article reviews the research progress of Bevacizumab and EGFR-TKI in the treatment of NSCLC.

Key words： Bevacizumab Epidermal growth factor receptor tyrosine kinase inhibitor Non-small cell lung cancer Combined treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xin-yi
	ZHANG Mei-yun▲

Cite this article:

ZHANG Xin-yi,ZHANG Mei-yun▲. Research progress of Bevacizumab combined with epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer[J]. 中国当代医药, 2020, 27(11): 27-30.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I11/27

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	Santarpia M，Daffina MG，Karachaliou N，et al.Targeted drugs in small-cell lung cancer[J].Transl Lung Cancer Res，2016，5（1）：51-70.
[3]	顾伟国，余锋，聂珊琳，等.非小细胞肺癌术后EGFR-TKI靶向辅助治疗的研究进展[J].临床肿瘤学杂志，2018，23（12）：1131-1134.
[4]	Redmond KL，Papafili A，Lawler M，et al.Overcoming resistance to targeted therapies in cancer[J].Semin Oncol，2015，42（6）：896-908.
[5]	王晨，陈淑珍.非小细胞肺癌治疗药物EGFR-TKIs 获得性耐药机制的研究进展[J].2019，53（8）：1364-1371.
[6]	韩睿，何勇.抗血管生成治疗在晚期NSCLC 的应用与进展[J].重庆医学，2018，47（15）：2064-2067.
[7]	Larsen AK，Ouaret D，EI O，et al.Targeting EGFR and VEGF（R）pathway cross-talk in tumor survival and angiogenesis[J].Pharmacol Ther，2011，131（1）：80-90.
[8]	翁克贵，蒋勇，王颖.贝伐珠单抗联合盐酸厄洛替尼治疗晚期非小细胞肺癌EGFR 不同外显子突变的疗效分析[J].2017，34（7）：1019-1023.
[9]	李萍，马薇，周荣.非小细胞肺癌靶向治疗药物的研究进展[J].药学与临床研究，2017，25（2）：130-136.
[10]	Otsuka K，Hata A，Takeshita J，et al.EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer[J].Cancer Chemother Pharmacol，2015，76（4）：835-841.
[11]	高映浩，侯恩存，甘川.非小细胞肺癌EGFR-TKI 获得性耐药后治疗策略的研究进展[J].现代肿瘤医学，2018，26（14）：2285-2289.
[12]	Li HY，Takayama K，Wang S，et al.Addition of bevacizumab enhances antitumor activity of erlotinib against nonsmall cell lung cancer xenograft depending on VEGF expression[J].Cancer Chemother Pharmacol，2014，74（6）：1297-1305.
[13]	Furugaki K，Fukumura J，Iwai T，et al.Impact of bevacizumab in combination with erlotinb on EGFR-mutated nonsmall cell lung cancer xenograft models with T790M mutation or MET amplification[J].Int J Cancer，2016，138（4）：1024-1032.
[14]	Masuda C，Yanagisawa M，Yorozu K，et al.Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFRmutated NSCLC xenograft model[J].Int J Oncol，2017，51（2）：425-434.
[16]	屈丽岩，康晓艳，宋霞.抗血管生成药物联合EGFR-TKI在晚期NSCLC 治疗中的应用[J].国际肿瘤学杂志，2017，44（1）：57-59.
[20]	李剑英，吴晓敏，何灵慧，等.EGFR-TKI 联合化疗治疗EGFR-TKI 获得性耐药的晚期非小细胞肺癌疗效分析[J].中国癌症杂志，2013，23（6）：462-466.
[21]	史钟，范云.EGFR 敏感突变NSCLC患者的最佳治疗模式探讨[J].中国肺癌杂志，2015，18（2）：110-116.
[22]	吴惠珍，邱学佳，段宝京，等.贝伐珠单抗联合厄洛替尼治疗NSCLC 疗效及安全性Meta分析[J].中华肿瘤防治杂志，2017，24（9）：637-643.
[15]	Ciuleanu T，Tsai CM，Tsao CJ，et al.A phase Ⅱstudy of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer[J].Lung Cancer，2013，82（2）：276-281.
[17]	Kazushi Y，Yasuhide Y.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer harboring EGFR mutations （JO25567）：an open-label，randomized，multicenter，phase Ⅱstudy[J].Transl Lung Cancer Res，2015，4（3）：217-219.
[18]	Terufumi K，Takashi S，Makoto N，et al.Erlotinib plus bevacizumab phase Ⅱstudy in patients with advanced nonsmall-cell lung cancer （JO25567）：updated safety results[J].Drug Saf，2018，41（2）：229-237.
[19]	Rosell R，Dafni U，Felip E，et al.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations （BELIEF）：an international，multicentre，single-arm，phase 2 trial[J].Lancet Respir Med，2017，5（5）：435-444.
[23]	Saito H，Fukuhara T，Furuya N，et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFRpositive advanced non-squamous non-small-cell lung cancer （NEJ026）：interim analysis of an open-label，randomized，multicenter，phase 3 trial[J].Lancet Oncol，2019，20（5）：625-635.
[24]	Yasuhiro C，Masatoshi K，Akihiro T，et al.Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer[J].Ann Transl Med，2018，6（20）：401-407.
[25]	Sakata Y，Kawamura K，Shingu N，et al.Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer[J].Lung Cancer，2016，99（6）：120-122.